22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
20:45 , Jul 11, 2019 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
01:04 , Jun 28, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

Pfizer Inc. (NYSE:PFE) appointed former FDA Commissioner Scott Gottlieb to its board. Gottlieb is joining the board's regulatory and compliance and science and technology committees. Since leaving the FDA in early April, Gottlieb returned to...
22:41 , May 2, 2019 |  BC Extra  |  Company News

Management tracks: Akero, NIH, Arcus

Metabolic disease company Akero Therapeutics Inc. (South San Francisco, Calif.) hired Bill White as its first CFO and head of corporate development. He was a managing director and head of U.S. life sciences investment banking...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
23:37 , Mar 26, 2019 |  BC Extra  |  Company News

Management tracks: Rubius, Abingworth, Arcus

Rubius hired Greg Whitehead as SVP and chief quality officer, a newly created position. He was VP, quality at bluebird bio Inc. (NASDAQ:BLUE). Whitehead will be responsible for defining the company's quality strategy to meet...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
20:46 , Oct 19, 2018 |  BioCentury  |  Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in...
18:26 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Taiho Ventures increases investment pool to $300M

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. The firm said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical...